Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy
This article was originally published in The Tan Sheet
Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.
You may also be interested in...
The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.
Procter & Gamble and Teva Pharmaceutical Industries combine their consumer businesses in a joint venture that creates a leading platform for Rx-to-OTC switches and new consumer health products.
Reckitt Benckiser continues expanding its Asian business with the purchase of Paras Pharmaceuticals Ltd., a top OTC manufacturer in India, where nonprescription drug sales are growing 23% annually.